Interleukin (IL)-11 is a member of the
IL-6 family of
cytokines that is defined by the shared use of the
GP130 signal transducing receptor subunit. In addition of its long recognized activities as a hemopoietic
growth factor,
IL-11 has an emerging role in epithelial
cancer biology. Through the activation of the GP130-Janus
kinase signaling cascade and associated
transcription factor STAT3,
IL-11 can confer many of the
tumor intrinsic 'hallmark' capabilities to neoplastic cells, if they express the
ligand-specific IL-11Rα receptor subunit. Accordingly,
IL-11 signaling has recently been identified as a rate-limiting step for the growth
tumors arising from the mucosa of the gastrointestinal tract. However, there is less appreciation for a potential role of
IL-11 to support
breast cancer progression, apart from its well documented capacity to facilitate bone
metastasis. Here we review evidence that
IL-11 expression in
breast cancer correlates with poor disease outcome and discuss some of the molecular mechanisms that are likely to underpin these observations. These include the capacity of
IL-11 to stimulate survival and proliferation of
cancer cells alongside angiogenesis of the primary
tumor and of metastatic progenies at distant organs. We review current strategies to interfere with
IL-11 signaling and advocate that inhibition of
IL-11 signaling may represent an emerging therapeutic opportunity for numerous
cancers.